Poxel EBITDA

Que fait Poxel ? Poxel SA is a biopharmaceutical company that focuses on the development of drugs for the treatment of metabolic disorders, particularly type 2 diabetes. The company was founded in Lyon, France, in 2009. The business model of Poxel SA is based on the targeted development of drugs for the treatment of metabolic disorders that are characterized by high medical demand and large market potential. The company focuses on the identification of drug candidates that are highly specific and effective, while also having a favorable safety profile. Poxel SA relies on close collaboration with academic research and the industry to leverage the latest knowledge and technologies in drug development. In recent years, Poxel SA has become a leading company in metabolic medicine and has an extensive product pipeline with a range of promising drug candidates. The product range of Poxel SA includes both preclinical and clinical candidates, as well as products that are already in advanced stages of clinical development. One of the main products of Poxel SA is Imeglimin, a drug for the treatment of type 2 diabetes. Imeglimin is a new compound that acts on the metabolic disorder in a new way and improves the body's glucose metabolism. The drug is currently in the final phase of clinical development and has already shown promising results in earlier studies. Another promising product of Poxel SA is PXL770, a drug for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). PXL770 is a novel compound that acts on the AMP-activated protein kinase system of the body and regulates the body's fat and glucose metabolism. The drug is still in the clinical phase of development, but has already shown promising results. Another promising product group of Poxel SA are the adenosine monophosphate (AMP) activators, which are also being developed for the treatment of metabolic disorders such as type 2 diabetes and fatty liver disease. The AMP activators act on the AMP-activated protein kinase system of the body and regulate fat and glucose metabolism. Poxel SA also works closely with partners in the pharmaceutical industry to develop and bring innovative drug candidates to market. The company has partnerships with leading companies such as Sumitomo Dainippon Pharma, Roivant Sciences, and Servier to expand and diversify its product pipeline. Overall, Poxel SA is an emerging company in metabolic medicine that focuses on the development of innovative drugs for the treatment of metabolic disorders. With a strong product pipeline and proven collaboration with academia and the industry, Poxel SA is a promising player in this growing market. Poxel est l'une des entreprises les plus populaires sur Eulerpool.